The replacement of dopamine (DA) neurons by transplanting fetal ventral midbrain is a potential restorative therapy for Parkinson's disease (PD). Embryonic stem (ES) cells are a realistic alternative to fetal cells for cell-based replacement therapies since they are renewable, can be controlled for cell type specificity and reproducibility of in vitro processing. We have derived DA neurons from primate and human ES cell sources. In this project we will determine the therapeutic potential of immature post-mitotic DA neurons derived from human ES cells by transplantation into a MPTP PD primate model. The MPTP primate model produced by chronic systemic infusions is currently the best available functional model for PD and L-DOPA related complications. These MPTP-treated primates develop the characteristic motor signs of the human disease, that also improve with L-DOPA in the model. As seen in PD patients, repeated L-DOPA administration induces abnormal involuntary movements; the L-DOPA induced dyskinesias. First, we will examine the capacity of transplanted post-mitotic DA neurons derived from human ES cells to improve PD signs in MPTP primates, in comparison to standard L-DOPA therapy. Detailed motor behavioral evaluation, functional neuroimaging using PET specific DA radiotracers and functional MRI will determine the functional effects of the transplanted DA neurons. Such data is then analyzed in conjunction with post mortem analyses of transplant cell composition, host reactions and connectivity.
Aim 2, determines the effects of the transplanted DA phenotype derived from primate ES cells (not requiring immune suppression) on dyskinesias. Dyskinesias are induced by repeated L-DOPA administration in stable MPTP PD model primates and then rated systematically before and after transplantation. Functional imaging studies in such animals will also be performed to examine maturation and functional integration of ES derived DA neurons into the host circuitry. The data, conclusion and hypotheses generated and data are analyzed further by addressing the corresponding the clinical and histological studies of transplanted PD patients (with human fetal DA neurons) performed in the neurohistology core. The PD focused work in this project is necessary to determine the growth, functional benefits and safety of human and primate ES cell derived DA neurons in a primate model of PD, in order to potentially translate the experimental hypothesis into clinically effective and safe procedures.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS039793-08
Application #
7426423
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
8
Fiscal Year
2007
Total Cost
$692,064
Indirect Cost
Name
Mclean Hospital
Department
Type
DUNS #
046514535
City
Belmont
State
MA
Country
United States
Zip Code
02478
Wang, Xin; Li, Nuomin; Xiong, Nian et al. (2017) Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson's Disease. Mol Neurobiol 54:2878-2888
Xiong, Nian; Li, Nuomin; Martin, Eden et al. (2016) hVMAT2: A Target of Individualized Medication for Parkinson's Disease. Neurotherapeutics 13:623-34
Hallett, Penelope J; Deleidi, Michela; Astradsson, Arnar et al. (2015) Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell 16:269-74
Hallett, Penelope J; Cooper, Oliver; Sadi, Damaso et al. (2014) Long-term health of dopaminergic neuron transplants in Parkinson's disease patients. Cell Rep 7:1755-61
Lindvall, Olle; Barker, Roger A; Brüstle, Oliver et al. (2012) Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell 10:151-5
Cooper, Oliver; Hallett, Penny; Isacson, Ole (2012) Using stem cells and iPS cells to discover new treatments for Parkinson's disease. Parkinsonism Relat Disord 18 Suppl 1:S14-6
Hallett, Penelope J; McLean, Jesse R; Kartunen, Andrew et al. (2012) ýý-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis 47:258-67
McLean, Jesse R; Hallett, Penelope J; Cooper, Oliver et al. (2012) Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol Cell Neurosci 49:230-9
Deleidi, Michela; Isacson, Ole (2012) Viral and inflammatory triggers of neurodegenerative diseases. Sci Transl Med 4:121ps3
Deleidi, Michela; Cooper, Oliver; Hargus, Gunnar et al. (2011) Oct4-induced reprogramming is required for adult brain neural stem cell differentiation into midbrain dopaminergic neurons. PLoS One 6:e19926

Showing the most recent 10 out of 91 publications